Wednesday, July 8, 2026

biotech · Chronic Inducible Urticaria · Chronic Spontaneous Urticaria · JSPR

Jasper Therapeutics

Jasper Therapeutics clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Redwood City, CA, US HQ
44 Employees
Public company Type
JSPR · NYSE Ticker
Company details
Status
Public
HQ
Redwood City, CA, US
Employees
44
Programs
13
Drugs
13
Patents
1
Intelligence · Clinical Programs

Jasper Therapeutics projects

4 ClinicalTrials.gov programs sponsored by Jasper Therapeutics.

Jasper Therapeutics has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Briquilimab

    Jasper Therapeutics

    Allergic Asthma

    phase 1 small molecule terminated

    1 trial
  2. Humanized anti-CD117 Monoclonal Antibody (JSP191)

    Jasper Therapeutics

    MYELODYSPLASTIC SYNDROME; MDS

    phase 1 mab active

    1 trial
  3. JSP-CP-012

    Jasper Therapeutics

    allergic asthma

    phase 1 other active

    1 trial
  4. JSP191

    Jasper Therapeutics

    Lower-risk Myelodysplastic Syndrome

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Jasper Therapeutics have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.